Clinical Trial Update: A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

The study ALT-801 in patients with BCG-failure non-muscle invasive bladder cancer (Phase 1/2) was terminated, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• ALT-801

Snippet

Sponsor: Altor BioScience | Conditions: Non-muscle Invasive Bladder Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-07-19